<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fungal peritonitis in peritoneal dialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fungal peritonitis in peritoneal dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fungal peritonitis in peritoneal dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel D Glickman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary M Cox, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infections of the peritoneal space are a common complication of peritoneal dialysis [<a href="#rid1">1</a>].</p><p>Among patients undergoing peritoneal dialysis, peritonitis is more commonly caused by bacteria than fungi. However, peritonitis caused by fungi carries a higher morbidity and mortality than bacterial infections. Reported complications include sclerosing peritonitis, adhesions with resulting bowel obstructions or stricture, invasion of the bowel wall, and abscess formation [<a href="#rid2">2</a>]. Extraperitoneal spread of infection is unusual, and mortality is usually related to underlying conditions.</p><p>An overview of fungal peritonitis in patients undergoing continuous peritoneal dialysis is presented in this topic review. A general overview of peritonitis in peritoneal dialysis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Among peritoneal dialysis patients, infections of the peritoneal space are usually caused by staphylococcal species. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Microbiology'</a>.)</p><p>By comparison, fungi are responsible for 2 to 13 percent of such cases. Most fungal peritoneal dialysis-associated infections are due to <em>Candida</em> species, especially <em>C. albicans</em> and <em>C. parapsilosis</em>. Assorted molds and yeasts, such as species of <em>Aspergillus</em> [<a href="#rid3">3</a>], <em>Fusarium</em>, <em>Rhodotorula</em>, <em>Mucorales</em>, and dematiaceous molds, are occasionally observed. Fungi, when found with bacteria as part of a polymicrobial peritonitis, are a predictor of a poor response to therapy [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CAUSES AND RISK FACTORS</span><span class="headingEndMark"> — </span>Causes of fungal contamination of peritoneal fluid include breaks in sterile technique when connecting peritoneal catheters to bags of dialysate, infections at the cutaneous site of catheter entry, intestinal perforation, peritoneovaginal fistulae, and transmigration of fungi across the bowel wall into the peritoneum.</p><p>Recent history of bacterial peritonitis and exposure to antibacterial agents increase the risk for fungal peritonitis. Almost all published series have found an association with both recent antibacterial use and episodes of fungal peritonitis [<a href="#rid1">1,5-10</a>]. When these series are combined, 65 percent of patients had been exposed to antibiotics within 30 days of the onset of fungal peritonitis, and 48 percent had experienced an episode of bacterial peritonitis within the same time frame.</p><p>It is difficult to determine whether antibiotic exposure and peritoneal inflammation actually predispose to fungal infections or whether these factors merely identify a high-risk group of patients prone to peritonitis because of poor technique. Recent exposure to antibiotics may predispose to fungal peritonitis by shifting the balance of the patients' endogenous skin and bowel microbiota towards yeast species, thereby increasing the chances of contamination during catheter manipulation.</p><p>Other risk factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of emergency peritoneal dialysis </strong>– A trend towards infection with fungal organisms has been observed in association with acute or emergent peritoneal dialysis performed in the hospital; this may be due to the severity of illness of these patients, concurrent treatment with antibacterial agents, or the administration of dialysis by personnel unfamiliar with the techniques associated with peritoneal dialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human immunodeficiency virus (HIV) infection </strong>– Patients with HIV infection who receive chronic peritoneal dialysis have a higher frequency of peritonitis with yeasts when compared with other chronic peritoneal dialysis patients. (See  <a class="medical medical_review" href="/z/d/html/1915.html" rel="external">"Human immunodeficiency virus and dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraperitoneal fungal infection</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal surgery</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental exposures </strong>– There are reports of outbreaks of <em>Candida </em>peritonitis associated with contamination of water baths used to warm dialysate solutions and even environmental contact with pigeon guano [<a href="#rid11">11,12</a>]. In addition, contact with soil during gardening or recreation may lead to peritonitis with certain molds.</p><p></p><p class="headingAnchor" id="H4"><span class="h1">SYMPTOMS AND SIGNS</span><span class="headingEndMark"> — </span>The symptoms and signs of fungal peritonitis in peritoneal dialysis patients are the same as those for bacterial peritonitis. The most consistent findings are a cloudy dialysate and abdominal pain, which occur in approximately 90 and 75 percent of patients, respectively. Abdominal pain that is usually diffuse may be associated with nausea, vomiting, and diarrhea. The symptoms may also be subtle, consisting of only mild abdominal pain and low-grade fever. (See  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p>The majority of patients have an elevated temperature; examination of the abdomen typically displays signs of peritonitis, including diffuse tenderness with guarding, rebound tenderness, abdominal distention, and decreased bowel sounds. Poor return of the dialysate during episodes of fungal peritonitis occurs more frequently with infections by molds, which can potentially block catheter ports.</p><p class="headingAnchor" id="H5"><span class="h1">LABORATORY FINDINGS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>When examining the dialysate fluid for fungal infection, attention should be paid to the duration of the dwell and whether or not peritoneal lavage was performed prior to sample collection; these factors can influence cell counts and culture. As for all peritoneal dialysis-associated peritonitis, the criterion for infection is a cell count &gt;100 cells/microL with &gt;50 percent polymorphonuclear cells. However, among patients with fungal peritonitis, the peritoneal white blood count is almost always &gt;200 cells/microL, with a polymorphonuclear cell predominance. (See  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Peritoneal fluid analysis'</a>.)</p><p>Although local eosinophilia is a frequent transient finding during the first few weeks after initiating peritoneal dialysis, peritoneal eosinophilia has also been described with certain mold infections [<a href="#rid13">13</a>]. The finding of eosinophils in the peritoneal fluid of a patient on chronic peritoneal dialysis with suspected infection should raise the consideration of fungi as etiologic agents, although a predominance of eosinophils may also be observed in bacterial peritonitis. (See  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Cell count and differential'</a>.)</p><p>Gram stain of the peritoneal fluid may reveal yeasts consistent with <em>Candida</em>. However, other stains, such as calcofluor white, are more sensitive for other fungi.</p><p>The diagnosis of fungal peritonitis is made by culturing the dialysate fluid. It is recommended that at least 10 mL (separated into multiple culture bottles) of peritoneal fluid be sent for fungal culture (see  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Evaluation'</a>). Although <em>Candida</em> species usually grow quickly in culture, other fungi may require weeks to emerge. The diagnosis therefore requires a high level of suspicion, with some cases presenting as culture-negative peritonitis.</p><p class="headingAnchor" id="H2876876477"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Observational data and two randomized controlled trials suggest that antifungal prophylaxis during the course of antibiotic therapy may reduce the incidence of fungal peritonitis [<a href="#rid14">14-18</a>]. Either <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> (500,000 units orally three to four times daily) or oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg every other day or 100 mg once daily) can be given to peritoneal dialysis patients who receive prolonged antibiotics (defined as antibiotic duration beyond a single dose). The optimal duration of antifungal prophylaxis is unclear, but many clinicians (including the authors of this topic) would administer prophylactic therapy for the duration of antibiotic treatment. Some clinicians extend the duration of antifungal prophylaxis by an additional three days in patients receiving aminoglycosides or by an additional seven days in those receiving <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> since these antibiotics have prolonged half-lives in patients on peritoneal dialysis [<a href="#rid18">18</a>]. Routine prophylaxis for all peritoneal dialysis patients (ie, in the absence of prolonged antibiotic therapy) is not recommended.</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1498692671"><span class="h2">General approach</span><span class="headingEndMark"> — </span>The goals of treatment are to eradicate infection and preserve the peritoneum for future use in peritoneal dialysis. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The peritoneum should be lavaged until the returning fluid is clear; this helps prevent adhesions and lowers the fungal burden.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic antifungals should be given if a calcofluor white or Gram stain reveals yeast or hyphae. Subsequent therapy is based upon culture results, susceptibility of the organism, and patient response. (See <a class="local">'Antifungal agent and duration'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The catheter should be removed immediately after fungi are identified by microscopy or culture and the patient should be placed on hemodialysis [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1">Decisions regarding the specific antifungal agent and duration are discussed below. (See <a class="local">'Antifungal agent and duration'</a> below.)</p><p></p><p class="headingAnchor" id="H2302329796"><span class="h2">Antifungal agent and duration</span><span class="headingEndMark"> — </span>The choice of antifungal agent varies based upon the specific infecting organism:</p><p class="bulletIndent1"><span class="glyph">●</span>For empiric coverage of fungal peritonitis until cultures return, we use <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg on day 1, followed by 100 to 200 mg/day). Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. Intravenous (IV) therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill. For patients who have had prior exposure to azole antifungals, we suggest IV <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.6 mg/kg per day) or an IV echinocandin (<a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> [70 mg on day 1, with subsequent dosing of 50 mg/day]; <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> [100 mg/day]; or <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> [200 mg on day 1, with subsequent dosing of 100 mg/day]) [<a href="#rid21">21-25</a>]. After cultures return, further therapy can be tailored to the specific organism that has been isolated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <em>Candida</em> species are found, susceptibility studies should be requested to help direct therapy. Generally, <em>C. albicans</em>, <em>C. parapsilosis</em>, and <em>C. tropicalis</em> are susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>; <em>C. krusei</em> is resistant; and <em>C. glabrata</em> has variable susceptibilities but generally is resistant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fluid cultures yield <em>C. albicans</em>, <em>C. tropicalis</em>, or <em>C. parapsilosis</em>, we use <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> at 200 mg orally on day 1, with subsequent dosing of 100 to 200 mg/day [<a href="#rid1">1,19,26-28</a>]. The duration of therapy is generally two to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fluid cultures yield <em>C. krusei</em> or <em>C. glabrata</em>, we suggest an IV echinocandin (<a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> [70 mg on day 1, with subsequent dosing of 50 mg/day]; <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> [100 mg/day]; or <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> [200 mg on day 1, with subsequent dosing of 100 mg/day]) or IV amphotericin B at a dose of 0.6 to 1 mg/kg per day [<a href="#rid21">21-25</a>]. Patients should be treated for four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fluid cultures yield a mold, we suggest IV <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> at 0.6 to 1 mg/kg per day until the specific organism is identified and the most appropriate antifungal agent can be given. For <em>Aspergillus</em> species or <em>Scedosporium apiospermum </em>complex, <strong>oral</strong> <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> should be used [<a href="#rid29">29</a>]. Patients should be treated for at least four weeks and until all symptoms and signs have resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections due to dematiaceous molds should be treated with oral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (loading dose of 400 mg twice daily for the first day, followed by 200 mg twice a day), although some cases have responded to IV amphotericin B [<a href="#rid30">30,31</a>]. Patients should be treated for at least four weeks and until all symptoms and signs have resolved. Patients receiving voriconazole should have serum levels checked to avoid toxicity and ensure adequate absorption, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is limited experience using lipid formulations of amphotericin B [<a href="#rid32">32,33</a>], but they should be as effective as the deoxycholate formulation. Lipid formulations should be used among patients who have residual kidney function in order to limit nephrotoxicity. These agents may also be used in patients who experience severe infusion-related reactions to the deoxycholate formulation. The dose is 3 to 5 mg/kg/day.</p><p></p><p>The experience with echinocandins in continuous ambulatory peritoneal dialysis (CAPD)-associated fungal peritonitis is only anecdotal [<a href="#rid21">21</a>]. However, all three echinocandins have proven effective for the treatment of candidemia. In all of the randomized, controlled trials of echinocandins for candidemia and invasive candidiasis, a small number of patients had peritoneal infection and responded well to the echinocandin agent [<a href="#rid22">22-25</a>].</p><p>Instillation of amphotericin B into the peritoneal cavity has occasionally been used as the sole or adjunctive therapy in the rare patient in whom the peritoneal dialysis catheter has not been removed. However, we do not use this regimen, because it is not consistently successful in curing infections, it causes abdominal pain upon instillation, and it can contribute to adhesion formation with subsequent loss of the peritoneum as a dialyzing membrane. In addition, catheter removal as part of the initial management of fungal peritonitis eliminates the possibility of intraperitoneal administration of antifungal agents.</p><p class="headingAnchor" id="H4108973586"><span class="h2">Timing of catheter replacement</span><span class="headingEndMark"> — </span>The patient should be maintained with hemodialysis during treatment with systemic antifungal agents. After peritoneal dialysis catheter removal, the catheter may be reinserted after at least two weeks of antifungal therapy and complete resolution of peritoneal symptoms.</p><p>However, the timing of replacement is complex and depends on the response to therapy and the severity of the initial event. In a study of 36 episodes of fungal peritonitis, peritoneal dialysis was eventually resumed in 12 cases, and the median time to catheter reinsertion was 15 weeks [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H8"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>Compared with other causes of peritonitis, fungal peritonitis in peritoneal dialysis is associated with decreased survival [<a href="#rid35">35</a>]. Reported mortality rates have ranged from 15 to 45 percent [<a href="#rid19">19,35,36</a>].</p><p class="headingAnchor" id="H2731329235"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H30746741"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Patients undergoing maintenance peritoneal dialysis have a markedly increased incidence of fungal infection compared with the general population. Fungi are responsible for 2 to 13 percent of all cases of peritoneal dialysis-associated peritonitis. Most fungal infections are due to <em>Candida</em> species. (See <a class="local">'Introduction'</a> above and <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The reasons for fungal peritonitis include breaks in sterile technique, infections at the cutaneous site of catheter entry, intestinal perforation, peritoneovaginal fistulae, and transmigration of fungi across the bowel wall into the peritoneum. Other risk factors include recent antibacterial use, episodes of bacterial peritonitis, emergent peritoneal dialysis, human immunodeficiency virus (HIV) infection, extraperitoneal fungal infection, abdominal surgery, and environmental exposures. (See <a class="local">'Causes and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The symptoms and signs of fungal peritonitis in peritoneal dialysis patients are the same as those for bacterial peritonitis. The most consistent findings are a cloudy dialysate and diffuse abdominal pain. Abdominal pain may be associated with nausea, vomiting, and diarrhea. The symptoms may also be subtle, consisting of only mild abdominal pain and low-grade fever. (See <a class="local">'Symptoms and signs'</a> above and  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The criterion for diagnosis of peritoneal dialysis-associated peritonitis is a peritoneal cell count &gt;100 cells/microL with &gt;50 percent polymorphonuclear cells; the cell count is usually &gt;200 cells/microL among patients with fungal peritonitis. Gram stain of the peritoneal fluid may reveal yeasts consistent with <em>Candida</em>. The diagnosis is made by culturing the dialysate fluid. (See <a class="local">'Laboratory findings and diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Cell count and differential'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The goals of treatment include both eradication of infection and preservation of the peritoneum for future use for dialysis. If the dialysate is grossly turbid, peritoneal lavage should be done until the returning fluid is clear. Systemic antifungals should be given, and the catheter should be removed as soon as possible. Prompt initiation of antifungal therapy is indicated if a calcofluor white or Gram stain reveals yeast or hyphae. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antifungal therapy</strong> – The choice of antifungal agent varies based upon the specific infecting organism:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg on day 1, followed by 100 to 200 mg/day) should be used for empiric coverage of fungal peritonitis when there is no suggestion of the identity of the fungus from inspection of the fluid and until cultures return.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intravenous (IV) <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.6 mg/kg per day) or an IV echinocandin (<a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> [70 mg on day 1, with subsequent dosing of 50 mg/day], <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> [100 mg/day], or <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> [200 mg on day 1, with subsequent dosing of 100 mg/day]) may be used for empiric coverage for patients who have had prior exposure to azole antifungals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tailoring therapy</strong> – After cultures return, further therapy can be tailored to the specific organism that has been isolated. If <em>Candida</em> species are found, susceptibility studies should be requested to help direct therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>C. albicans</em>, <em>C. tropicalis</em>, or <em>C. parapsilosis</em>, we use <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> at 200 mg on day 1, with subsequent dosing of 100 to 200 mg/day. Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill. The duration of therapy is generally two to four weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>C. krusei</em> or <em>C. glabrata</em>, we use an IV echinocandin (<a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> [70 mg on day 1, with subsequent dosing of 50 mg/day], <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> [100 mg/day], or <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> [200 mg on day 1, with subsequent dosing of 100 mg/day]) or IV <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> at a dose of 0.6 to 1 mg/kg per day. Patients should be treated for four weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For a mold, we use IV <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> at 0.6 to 1 mg/kg per day until the specific organism is identified and the most appropriate antifungal agent can be given.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>Aspergillus</em> species or <em>Scedosporium</em> <em>apiospermum</em> complex, oral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> should be used. Patients should be treated for at least four weeks and until all symptoms and signs have resolved.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Infections due to dematiaceous molds should be treated with oral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (loading dose of 400 mg twice daily for the first day, followed by 200 mg twice a day). Patients should be treated for at least four weeks and until all symptoms and signs have resolved.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If amphotericin B is required for treatment, lipid formulations should be used in those who have residual kidney function to limit nephrotoxicity. These agents may also be used in patients who experience severe infusion-related reactions to the deoxycholate formulation. The dose is 3 to 5 mg/kg/day. Although there is limited experience using lipid formulations of amphotericin B for treatment of fungal peritonitis, they should be as effective as the deoxycholate formulation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of catheter replacement</strong> – The patient should be maintained with hemodialysis during treatment with systemic antifungal agents. After peritoneal dialysis catheter removal, the catheter may be reinserted after at least two weeks of antifungal therapy and complete resolution of peritoneal symptoms. However, the timing of catheter replacement is complex and depends on the response to therapy and the severity of the initial event. (See <a class="local">'Timing of catheter replacement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of prophylaxis</strong> – Antifungal prophylaxis during the course of antibiotic therapy may reduce the incidence of fungal peritonitis. For peritoneal dialysis patients who receive prolonged antibiotics (defined as antibiotic duration beyond a single dose), we suggest the administration of antifungal prophylaxis with <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> (500,000 units orally three to four times daily) or <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg every other day or 100 mg once daily). We recommend not providing routine prophylaxis for all peritoneal dialysis patients (ie, in the absence of prolonged antibiotic therapy). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H2814742313"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steve J Schwab, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005; 25:207.</a></li><li><a class="nounderline abstract_t">Uchida M, Sakemi T, Nagano Y, Mizuguchi M. Rectal stenosis associated with fungal peritonitis: a complication of continuous ambulatory peritoneal dialysis. Nephron 1989; 53:288.</a></li><li><a class="nounderline abstract_t">Schwetz I, Horina J, Buzina W, et al. Aspergillus oryzae peritonitis in CAPD: case report and review of the literature. Am J Kidney Dis 2007; 49:701.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Wong TY, et al. Conservative management of polymicrobial peritonitis complicating peritoneal dialysis--a series of 140 consecutive cases. Am J Med 2002; 113:728.</a></li><li><a class="nounderline abstract_t">Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.</a></li><li><a class="nounderline abstract_t">Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 1986; 8:309.</a></li><li><a class="nounderline abstract_t">Nagappan R, Collins JF, Lee WT. Fungal peritonitis in continuous ambulatory peritoneal dialysis--the Auckland experience. Am J Kidney Dis 1992; 20:492.</a></li><li><a class="nounderline abstract_t">Rubin J, Kirchner K, Walsh D, et al. Fungal peritonitis during continuous ambulatory peritoneal dialysis: a report of 17 cases. Am J Kidney Dis 1987; 10:361.</a></li><li><a class="nounderline abstract_t">Tapson JS, Mansy H, Freeman R, Wilkinson R. The high morbidity of CAPD fungal peritonitis--description of 10 cases and review of treatment strategies. Q J Med 1986; 61:1047.</a></li><li><a class="nounderline abstract_t">Bren A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1998; 17:839.</a></li><li><a class="nounderline abstract_t">Greaves I, Kane K, Richards NT, et al. Pigeons and peritonitis? Nephrol Dial Transplant 1992; 7:967.</a></li><li><a class="nounderline abstract_t">Yuen KY, Seto WH, Ching TY, et al. An outbreak of Candida tropicalis peritonitis in patients on intermittent peritoneal dialysis. J Hosp Infect 1992; 22:65.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Pacey D, Gordon DL. Peritoneal eosinophilia associated with Paecilomyces variotii infection in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18:603.</a></li><li><a class="nounderline abstract_t">Záruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am J Kidney Dis 1991; 17:43.</a></li><li><a class="nounderline abstract_t">Moreiras-Plaza M, Vello-Román A, Sampróm-Rodríguez M, Feijóo-Piñeiro D. Ten years without fungal peritonitis: a single center's experience. Perit Dial Int 2007; 27:460.</a></li><li><a class="nounderline abstract_t">Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007; 27:531.</a></li><li><a class="nounderline abstract_t">Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Perit Dial Int 2010; 30:619.</a></li><li><a class="nounderline abstract_t">Lo WK, Chan CY, Cheng SW, et al. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:549.</a></li><li><a class="nounderline abstract_t">Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36:1183.</a></li><li><a class="nounderline abstract_t">Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</a></li><li><a class="nounderline abstract_t">Madariaga MG, Tenorio A, Proia L. Trichosporon inkin peritonitis treated with caspofungin. J Clin Microbiol 2003; 41:5827.</a></li><li><a class="nounderline abstract_t">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a class="nounderline abstract_t">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a class="nounderline abstract_t">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a class="nounderline abstract_t">Cousin L, Berre ML, Launay-Vacher V, et al. Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant 2003; 18:2227.</a></li><li><a class="nounderline abstract_t">Chan TM, Chan CY, Cheng SW, et al. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. Nephrol Dial Transplant 1994; 9:539.</a></li><li><a class="nounderline abstract_t">Vas S, Oreopoulos DG. Infections in patients undergoing peritoneal dialysis. Infect Dis Clin North Am 2001; 15:743.</a></li><li><a class="nounderline abstract_t">Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.</a></li><li><a class="nounderline abstract_t">Greig J, Harkness M, Taylor P, et al. Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis. Clin Microbiol Infect 2003; 9:713.</a></li><li><a class="nounderline abstract_t">Lau SK, Woo PC, Chiu SK, et al. Early diagnosis of Exophiala CAPD peritonitis by 18S ribosomal RNA gene sequencing and its clinical significance. Diagn Microbiol Infect Dis 2003; 46:95.</a></li><li><a class="nounderline abstract_t">Serna JH, Wanger A, Dosekun AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. Am J Kidney Dis 2003; 42:E14.</a></li><li><a class="nounderline abstract_t">Nannini EC, Paphitou NI, Ostrosky-Zeichner L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003; 46:49.</a></li><li><a class="nounderline abstract_t">Nadeau-Fredette AC, Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Perit Dial Int 2015; 35:78.</a></li><li class="breakAll">Tzamaloukas AH, Fox L. Infections in patients on peritoneal dialysis. In: Principles and Practice of Dialysis, Henrich WL (Ed), Lippincott, Williams &amp; Wilkins, New York 2004.</li><li><a class="nounderline abstract_t">Amici G, Grandesso S, Mottola A, et al. Fungal peritonitis in peritoneal dialysis: critical review of six cases. Adv Perit Dial 1994; 10:169.</a></li></ol></div><div id="topicVersionRevision">Topic 1982 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981767" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fungal peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2797355" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rectal stenosis associated with fungal peritonitis: a complication of continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472853" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aspergillus oryzae peritonitis in CAPD: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Conservative management of polymicrobial peritonitis complicating peritoneal dialysis--a series of 140 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602540" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523695" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442761" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fungal peritonitis in continuous ambulatory peritoneal dialysis--the Auckland experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3674010" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fungal peritonitis during continuous ambulatory peritoneal dialysis: a report of 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3659247" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The high morbidity of CAPD fungal peritonitis--description of 10 cases and review of treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052546" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1328948" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pigeons and peritonitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1358948" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An outbreak of Candida tropicalis peritonitis in patients on intermittent peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951343" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Peritoneal eosinophilia associated with Paecilomyces variotii infection in continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986569" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602157" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ten years without fungal peritonitis: a single center's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704443" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634438" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840945" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096043" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264029" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662994" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trichosporon inkin peritonitis treated with caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490683" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of caspofungin and amphotericin B for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568028" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anidulafungin versus fluconazole for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806055" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482982" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551347" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dosing guidelines for fluconazole in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090334" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11570140" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infections in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167683" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925114" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12812724" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early diagnosis of Exophiala CAPD peritonitis by 18S ribosomal RNA gene sequencing and its clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12955706" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742319" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497586" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Characteristics and outcomes of fungal peritonitis in a modern North American cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497586" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Characteristics and outcomes of fungal peritonitis in a modern North American cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999820" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fungal peritonitis in peritoneal dialysis: critical review of six cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
